AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04821947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine
Description: for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine
Study NCT04645511 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Description: The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides.
Study NCT04850937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
Study NCT04850937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
Study NCT05518019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The Daily Supplement
Description: Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol
Study NCT05922007 — intervention group
Intervention type: OTHER
Intervention: Validation of the Questionnaire
Description: Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
Study NCT05922007 — intervention group
Intervention type: OTHER
Intervention: Prospective quantitative study - questionnaire survey
Description: A questionnaire survey will be carried out using the questionnaire set three times
Study NCT04263766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
Study NCT06362577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG
Description: Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
Study NCT05431192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training + Enhanced Usual Care
Description: Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice.
Study NCT05431192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study.
Study NCT06453343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach: cochleostomy or extended round window
Description: Surgical placement of a cochlear implant electrode array
Study NCT06481020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols 2g/day
Description: PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
Study NCT06481020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet containing the powdered excipients of the dietary supplement during 8 weeks
Study NCT05823870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6014
Description: Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast
Study NCT04310865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinhu Qingwen Granula
Description: Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Study NCT04310865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yin Hu Qing Wen Granula(low does)
Description: This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
Study NCT04310865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical treatment
Description: Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
Study NCT04310865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard medical treatment
Description: Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
Study NCT05142163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative SVV Guided Fluid Therapy
Description: Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
Study NCT05142163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative PVI Guided Fluid Therapy
Description: Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values >10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
Study NCT06204588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group: SFA only
Description: Single flap approach
Study NCT06204588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 1: VCMX + Low level LASER therapy + Single flap approach
Description: using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
Study NCT06204588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 2: Low level LASER therapy + Single flap approach
Description: Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
Study NCT04826783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lasers
Description: The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
Study NCT04949503 — intervention group
Intervention type: DRUG
Intervention: nimotuzumab
Description: Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
Study NCT05106335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab + famitinib
Description: camrelizumab for intravenous injection; famitinib malate capsules for oral administration
Study NCT05106335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib
Description: famitinib malate capsules for oral administration
Study NCT05106335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel for intravenous injection
Study NCT05009680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
Study NCT05009680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally twice a day
Study NCT06138990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacoscopy
Description: Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
Study NCT06138990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical standard-of-care (physician's choice)
Description: Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
Study NCT05398861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Combined with Bevacizumab
Description: Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
Study NCT04679662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (PLAR Implant and Delivery System)
Description: The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
Study NCT04763564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
Study NCT04763564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pen Injector
Description: Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
Study NCT06396598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Review education materials
Study NCT06396598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06396598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Participate use the electronic symptom monitoring program to log symptoms
Study NCT06396598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch a video
Study NCT06396598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05698758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrometropine and 0.9% sodium chloride solution
Description: Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
Study NCT05698758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrometropine and 0.9% sodium chloride solution
Description: Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
Study NCT05806060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
Description: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
Study NCT05806060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel, with maintenance of capecitabine
Description: Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
Study NCT05806060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1
Description: TPC
Study NCT05806060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR and TPC
Description: VEGFR bevacizumab and TPC
Study NCT05736978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 d1-7
Study NCT05736978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: d1 100mg, d2 200mg, d3-28 400mg
Study NCT05736978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: if MRD positive in C1D14, selinexor 60mg D15, D22
Study NCT05433636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: Patients will listen to a 5-minute, audio-recorded body scan practice.
Study NCT05433636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
Study NCT05433636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of Discomfort
Description: Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
Study NCT05433636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Savoring
Description: Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
Study NCT05433636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrative Health Recording
Description: Patients will listen to a 5-minute, audio-recorded description of integrative health.
Study NCT04859621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
Study NCT04859621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Description: Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
Study NCT04859621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
Study NCT04859621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard antibiotic therapy
Description: standard antibiotic therapy
Study NCT04859621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard antibiotic therapy
Description: standard antibiotic therapy
Study NCT05693207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: wearables EMG
Study NCT05693207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMG
Description: wearables EMG
Study NCT05640336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Debridement, Antibiotics and Implant Retention
Description: Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
Study NCT05640336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned Double Debridement, Antibiotics and Implant Retention
Description: Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
Study NCT05323331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training Exercise Program
Description: The participants allocated to this group will perform Circuit Training Exercise Program
Study NCT05323331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Exercise Program
Description: The participants allocated to this group will perform Circuit Training Exercise Program
Study NCT06126068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia
Description: Loading dose magnesium sulfate versus the Pritchard regimen
Study NCT06486961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeatMove Application
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
Study NCT06486961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BeatMove Application without synchronized music
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
Study NCT06486961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BeatMove Application without music
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
Study NCT05744323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
Study NCT06299917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WORK-ON
Description: The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
Study NCT04809883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoflip measurement of gastric and pyloric function
Description: Endoflip device to measure gastric and pyloric functions
Study NCT05298319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
Study NCT05727072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered IV.
Study NCT05727072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered SC.
Study NCT05727072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT05727072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT05492253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant fruit
Description: Infants will be fed prune puree